FIA
NAVB

FNY Investment Advisers’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

FNY Investment Advisers’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-105,000
Closed -$413K – 694
2020
Q2 		$413K Sell
105,000
-94,220
-47% -$180K 0.24% 95
2020
Q1 		$151K Buy
+199,220
New +$220K 0.11% 140

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FNY Investment Advisers's NAVB Position: Q3 2020 in Review

FNY Investment Advisers sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2020, closing a stake of 105,000 shares — an estimated $413K sold.

FNY Investment Advisers first reported a position in NAVB in Q1 2020 and held it in 2 quarters. The position peaked at $413K in Q2 2020. 38 funds tracked by Wall St. Rank hold NAVB as of Q3 2020.

  • FNY Investment Advisers reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2020 after selling out during the quarter.
  • FNY Investment Advisers sold 105,000 Navidea Biopharmaceuticals Inc. shares in Q3 2020, an estimated $413K.
  • FNY Investment Advisers first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2020 and held it in 2 quarters.
  • FNY Investment Advisers's Navidea Biopharmaceuticals Inc. position peaked at $413K in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2020.

Based on FNY Investment Advisers's 13F filing for Q3 2020, filed 9 Oct 2020.